CONTACT
SBMT OFFICIAL EVENT

Brain Mapping Day
US Congress

Bridging neuroscience leadership and federal policymakers to advance the clinical translation of neurotechnology.

GET TICKETS DOWNLOAD PROSPECTUS
March 26 2026US Congress Washington DCRoom 340 Cannon BuildingNeurotechnology Policy ForumSBMT Official EventMarch 26 2026US Congress Washington DCRoom 340 Cannon BuildingNeurotechnology Policy ForumSBMT Official Event
About the Event

Where Neuroscience Meets Federal Policy

Brain Mapping Day at the US Congress brings together global neurotechnology leaders and policymakers to shape the future of brain health policy.

Neurological disorders cost the United States over $1.6 trillion annually. Brain Mapping Day exists to connect scientific innovation with the policy frameworks needed to deliver real clinical impact.

Each year, researchers, physicians, technology leaders, and legislators gather in the halls of Congress to accelerate the translation of neuroscience into real-world healthcare solutions.

13
Annual Editions
$1.6T
Annual Cost
2004
SBMT Founded
3B+
Global Patients
Why Attend

Why You Should Be In The Room

Direct Congressional Access

Engage directly with federal legislators and staff shaping neurotechnology policy.

Scientific Leadership

Hear from the world's leading neuroscientists and clinicians.

Global Network

Join the international SBMT neurotechnology community.

Program

A Day of Impact

SBMT Official Event  ·  13th Annual Edition

Annual Brain Mapping Day at the U.S. Congress

13th Congressional Briefing  ·  Washington, DC, USA

March 26, 2026 8:00 AM – 11:30 AM EDT Canon House Office Building, Room 340
Moderator

Babak Kateb, MD, PhD

Founding Chairman of the Board, Chief Executive Officer, and Scientific Director, Society for Brain Mapping and Therapeutics (SBMT); President, World Brain Mapping Foundation (WBMF); Director, Brain Technology and Innovation Park (BTIP); Director, National Center for Nano-Bio-Electronics (NCNBE); President and Chief Executive Officer, Aramis Therapeutics, Los Angeles, CA, USA

Program Co-ord.

Giridhar Solasa, MD

Chief Research Fellow, Society for Brain Mapping and Therapeutics (SBMT), USA

Scientific Program Schedule
All times EDT
08:00 – 08:10
Opening

Welcome, Registration & Networking

08:10 – 08:15
Opening Remarks

Opening Remarks

  • Babak Kateb, MD, PhD — Founding Chairman of the Board, Chief Executive Officer, and Scientific Director, SBMT; President, WBMF; Director, BTIP; Director, NCNBE; President and Chief Executive Officer, Aramis Therapeutics, USA
08:15 – 08:30
Congressional Address

Congressional Address

  • Hon. Congressman Eric Swalwell — U.S. Representative, California's 14th Congressional District; Member, U.S. House of Representatives
08:30 – 08:45
Congressional Address

Congressional Address

  • Hon. Congresswoman Dr. Judy Chu — Psychologist; U.S. Representative, California's 28th Congressional District; Member, U.S. House of Representatives
08:45 – 09:00
Break

Break and Networking

09:00 – 09:15
Congressional Address

Congressional Address

  • Hon. Congressman Bill Foster — U.S. Representative, Illinois's 11th Congressional District; Member, U.S. House of Representatives
09:15 – 09:30
Scientific Panel A

Neurotechnology and Innovation in Brain Health

  • Babak Kateb, MD, PhD — Founding Chairman of the Board, Chief Executive Officer, and Scientific Director, SBMT; President, WBMF; Director, BTIP; Director, NCNBE; President and Chief Executive Officer, Aramis Therapeutics, USA
  • Galen Buckwalter, PhD — Research Participant, California Institute of Technology; CEO, PsyML, Los Angeles, CA, USA
  • Rob Franklin, PhD — Senior Vice President, Brain-Computer Interfaces; Blackrock Neurotech, USA
BCINeurophotonicsAI
09:30 – 09:45
Panel Discussion

State-of-the-Art Neurotechnology and Innovation

Brain–Computer Interfaces (BCI), Neurophotonics, Nanoneuroscience, Predictive Modeling, Artificial Intelligence, Quantum Computing, and Neuromorphic Systems Shaping Next-Generation Brain Health Solutions

  • Allanah Beazley, MA — Public Affairs; Blackrock Neurotech, Salt Lake City, UT, USA
QuantumNeuromorphic
09:45 – 10:00
Congressional Address

Congressional Address

  • Hon. Congresswoman Kelly Morrison — U.S. Representative, Minnesota's 3rd Congressional District; Member, U.S. House of Representatives
10:00 – 10:15
Scientific Panel B

Advances in Neurotrauma and Psychiatric Disorders: Science and Clinical Translation

Brain Injury Myths Busted: Challenging Assumptions in Diagnosis and Treatment

  • Mandi Dickey, MSN, FNP-BC, RN, CBIS — Nurse Practitioner; Minneapolis Clinic of Neurology, Minneapolis, MN, USA
  • David Keyser, PhD — Deputy Director, Traumatic Injury Research Program; Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA

Toward Multiscale Precision Psychiatry: Defining the Next Paradigm

  • Nagy Youssef, MD, PhD — Vice President for Research; Director; Professor of Psychiatry and Behavioral Medicine; Pine Rest Christian Mental Health Services; Michigan State University College of Human Medicine, Grand Rapids, MI, USA
NeurotraumaTBIPsychiatry
10:15 – 10:30
Panel Discussion

Neurotrauma & Psychiatry: Integrating Technological Innovation Into Clinical Practice

  • Carlos Alberto Bezerra Tomaz, MD, PhD — Professor of Neuroscience; CEUMA University, São Luís, Brazil
  • Christina Demirelli — Spinal Cord Injury Patient Advocate; Society for Brain Mapping and Therapeutics (SBMT), USA
  • Nancy Torres — Certified Nurse Assistant
10:30 – 10:45
Congressional Address

Congressional Address

  • Hon. Congresswoman Yassamin Ansari — U.S. Representative, Arizona's 3rd Congressional District; Member, U.S. House of Representatives
10:45 – 10:50
Break

Break & Networking

10:50 – 11:10
Scientific Panel C

Neuro-oncology and Neurodegenerative Disorders: Integrated AI and Therapeutics

Current Status and Future of Cancer Research

  • Vicky Yamamoto, PhD — Executive Director, SBMT; Vice President, WBMF; Chief Scientist, Aramis Therapeutics, USA

Importance of Supporting Multitarget and Combination Strategies for Treating Complex Neurodegenerative Diseases Such as Alzheimer's Disease and Parkinson's Disease

  • Jessica Sonia Fortin, BPharm, BS-MS, DVM, PhD, DACVP, DABT — Assistant Professor, College of Veterinary Medicine, Purdue University, Indiana, USA

Artificial Intelligence in Neurological Diseases: Policy Priorities for Improved Outcomes

  • Farzad Khalvati, PhD, MASc — Director of Radiology Artificial Intelligence; Senior Scientist; Associate Professor; The Hospital for Sick Children; University of Toronto, Toronto, Canada

Amyloid and Tau PET Imaging in the Era of Disease-Modifying Therapies

  • Ana M. Franceschi, MD, PhD — Associate Professor of Radiology; Director of Dementia Imaging; Director of Molecular Neuroimaging; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA
Neuro-oncologyAlzheimer'sParkinson'sAI PolicyPET Imaging
11:10 – 11:25
Panel Discussion

Artificial Intelligence in Neuro-Oncology and Neurosurgical Disorders

11:25 – 11:30
Closing

Closing Remarks

  • Babak Kateb, MD, PhD — CEO, SBMT; President, WBMF

Join the Leaders Shaping the Future of Brain Science

Brain Mapping Day at the US Congress is where neuroscience innovation meets public policy.

Get Tickets
27 28 29